Here are preliminary results of the bibliometric mapping of the 2022 Luxembourg research evaluation. Its purpose is:
The method for the research-field-mapping can be reviewed here:
Note: The analysis in this document depicts the larger research field around the department, thereby all analysis results are based on the publications of the department plus related
Note: The seed articles deemed representative for
the active areas of research in the institution, and include authors
affiliated with the institution. The departments research field is
identified by selecting the 2000 most similar publications to the
selected seed articles. See Technical descriptionfor
additional explanations.
| AU | PY | TI | JI |
|---|---|---|---|
| KIWELER N;DELBROUCK C;POZDE… | 2022 | MITOCHONDRIA PRESERVE AN AUTARKIC ONE-CARBON CYCLE TO CONFER GROWTH-INDEPENDENT CANCER CELL MIGRA… | NAT. COMMUN. |
| SHARMA AB;ERASIMUS H;PINTO … | 2021 | XAB2 PROMOTES KU EVICTION FROM SINGLE-ENDED DNA DOUBLE-STRAND BREAKS INDEPENDENTLY OF THE ATM KINASE | NUCLEIC ACIDS RES. |
| GOLEBIEWSKA A;HAU A-C;OUDIN… | 2020 | PATIENT-DERIVED ORGANOIDS AND ORTHOTOPIC XENOGRAFTS OF PRIMARY AND RECURRENT GLIOMAS REPRESENT RE… | ACTA NEUROPATHOL. |
| NOMAN MZ;PARPAL S;VAN MOER … | 2020 | INHIBITION OF VPS34 REPROGRAMS COLD INTO HOT INFLAMED TUMORS AND IMPROVES ANTI-PD-1/PD-L1 IMMUNOT… | SCI. ADV. |
| WIERZ M;PIERSON S;GUYONNET … | 2018 | DUAL PD1/LAG3 IMMUNE CHECKPOINT BLOCKADE LIMITS TUMOR DEVELOPMENT IN A MURINE MODEL OF CHRONIC LY… | BLOOD |
Note: This section provides basic descriptives of th
identified research fielld, including number of articles over time,
countries, institutions, and authors. See
Technical descriptionfor additional explanations.
Note: Here, we report the results of a LDA
topic-modelling (basically, clustering on words) on all title+abstract
texts. Identified topics can be interpreted as broad themes in the
research field. See Technical descriptionfor additional
explanations.
Note: While this static vies is helpful, I recommend using the interactive LDAVis version to be found under https://daniel-hain.github.io/biblio_lux_2022/output/topic_modelling/LDAviz_lih_dcr.rds/index.html#topic=1&lambda=0.60&term=. For functionality and usage, see ´Technical ´.
Note: This analysis refers the co-citation analysis,
where the cited references and not the original publications are the
unit of analysis. Identified knowledge bases can be interpreted as the
knowledge foundation the field draws from. See
Technical descriptionfor additional explanations.
| name | dgr_int | dgr |
|---|---|---|
| Knowledge Base 1: KB 1: Immune checkpoint therapy in cancer (n = 2403, density =2.82) | ||
| PARDOLL D.M. THE BLOCKADE OF IMMUNE CHECKPOINTS IN CANCER IMMUNOTHERAPY (2012) | 9566 | 9783 |
| POSTOW M.A. CALLAHAN M.K. WOLCHOK J.D. IMMUNE CHECKPOINT BLOCKADE IN CANCER THERAPY (2015) | 4377 | 4419 |
| TOPALIAN S.L. HODI F.S. BRAHMER J.R. SAFETY ACTIVITY AND IMMUNE CORRELATES OF ANTI-PD-1 ANTIBODY IN CANCER (2012) | 2312 | 2360 |
| TUMEH P.C. HARVIEW C.L. YEARLEY J.H. PD-1 BLOCKADE INDUCES RESPONSES BY INHIBITING ADAPTIVE IMMUNE RESISTANCE (2014) | 2199 | 2234 |
| TUMEH P.C. HARVIEW C.L. YEARLEY J.H. SHINTAKU I.P. TAYLOR E.J. ROBERT L. PD-1 BLOCKADE INDUCES RESPONSES BY INHIBITING ADAPTIVE IMMUNE RESISTANCE (… | 1919 | 1980 |
| TOPALIAN S.L. TAUBE J.M. ANDERS R.A. PARDOLL D.M. MECHANISM-DRIVEN BIOMARKERS TO GUIDE IMMUNE CHECKPOINT BLOCKADE IN CANCER THERAPY (2016) | 1767 | 1829 |
| BORGHAEI H. PAZ-ARES L. HORN L. NIVOLUMAB VERSUS DOCETAXEL IN ADVANCED NONSQUAMOUS NON-SMALL-CELL LUNG CANCER (2015) | 1736 | 1750 |
| SHARMA P. ALLISON J.P. THE FUTURE OF IMMUNE CHECKPOINT THERAPY (2015) | 1710 | 1739 |
| BRAHMER J. RECKAMP K.L. BAAS P. NIVOLUMAB VERSUS DOCETAXEL IN ADVANCED SQUAMOUS-CELL NON-SMALL-CELL LUNG CANCER (2015) | 1672 | 1700 |
| TOPALIAN S.L. DRAKE C.G. PARDOLL D.M. IMMUNE CHECKPOINT BLOCKADE: A COMMON DENOMINATOR APPROACH TO CANCER THERAPY (2015) | 1487 | 1511 |
| Knowledge Base 2: KB 2: energy metabolism in cancer (n = 1998, density =4.04) | ||
| LOCASALE J.W. SERINE GLYCINE AND ONE-CARBON UNITS: CANCER METABOLISM IN FULL CIRCLE (2013) | 3951 | 4020 |
| HANAHAN D. WEINBERG R.A. HALLMARKS OF CANCER: THE NEXT GENERATION (2011) | 3505 | 6831 |
| VANDER HEIDEN M.G. CANTLEY L.C. THOMPSON C.B. UNDERSTANDING THE WARBURG EFFECT: THE METABOLIC REQUIREMENTS OF CELL PROLIFERATION (2009) | 3357 | 3742 |
| WARBURG O. ON THE ORIGIN OF CANCER CELLS (1956) | 2843 | 3008 |
| PAVLOVA N.N. THOMPSON C.B. THE EMERGING HALLMARKS OF CANCER METABOLISM (2016) | 2809 | 3059 |
| FAN J. YE J. KAMPHORST J.J. SHLOMI T. THOMPSON C.B. RABINOWITZ J.D. QUANTITATIVE FLUX ANALYSIS REVEALS FOLATE-DEPENDENT NADPH PRODUCTION (2014) | 2495 | 2514 |
| POSSEMATO R. MARKS K.M. SHAUL Y.D. PACOLD M.E. KIM D. BIRSOY K. SETHUMADHAVAN S. JHA A.K. FUNCTIONAL GENOMICS REVEAL THAT THE SERINE SYNTHESIS PATH… | 2312 | 2363 |
| PISKOUNOVA E. AGATHOCLEOUS M. MURPHY M.M. HU Z. HUDDLESTUN S.E. ZHAO Z. LEITCH A.M. MORRISON S.J. OXIDATIVE STRESS INHIBITS DISTANT METASTASIS BY H… | 2067 | 2085 |
| LOCASALE J.W. GRASSIAN A.R. MELMAN T. LYSSIOTIS C.A. MATTAINI K.R. BASS A.J. HEFFRON G. SHARFI H. PHOSPHOGLYCERATE DEHYDROGENASE DIVERTS GLYCOLYTIC… | 2021 | 2049 |
| SULLIVAN L.B. GUI D.Y. HOSIOS A.M. BUSH L.N. FREINKMAN E. VANDER HEIDEN M.G. SUPPORTING ASPARTATE BIOSYNTHESIS IS AN ESSENTIAL FUNCTION OF RESPIRAT… | 1711 | 1733 |
| Knowledge Base 3: KB 3: DNA damage and repair mechanisms in cancer 1 (n = 1743, density =4.4) | ||
| CICCIA A. ELLEDGE S.J. THE DNA DAMAGE RESPONSE: MAKING IT SAFE TO PLAY WITH KNIVES (2010) | 2610 | 4267 |
| JACKSON S.P. BARTEK J. THE DNA-DAMAGE RESPONSE IN HUMAN BIOLOGY AND DISEASE (2009) | 2175 | 2792 |
| MIMITOU E.P. SYMINGTON L.S. SAE2 EXO1 AND SGS1 COLLABORATE IN DNA DOUBLE-STRAND BREAK PROCESSING (2008) | 2031 | 2283 |
| SYMINGTON L.S. GAUTIER J. DOUBLE-STRAND BREAK END RESECTION AND REPAIR PATHWAY CHOICE (2011) | 1861 | 2221 |
| SARTORI A.A. LUKAS C. COATES J. MISTRIK M. FU S. BARTEK J. BAER R. JACKSON S.P. HUMAN CTIP PROMOTES DNA END RESECTION (2007) | 1773 | 2149 |
| HUERTAS P. JACKSON S.P. HUMAN CTIP MEDIATES CELL CYCLE CONTROL OF DNA END RESECTION AND DOUBLE STRAND BREAK REPAIR (2009) | 1668 | 1768 |
| CANNAVO E. CEJKA P. SAE2 PROMOTES DSDNA ENDONUCLEASE ACTIVITY WITHIN MRE11-RAD50-XRS2 TO RESECT DNA BREAKS (2014) | 1652 | 1809 |
| ZHU Z. CHUNG W.H. SHIM E.Y. LEE S.E. IRA G. SGS1 HELICASE AND TWO NUCLEASES DNA2 AND EXO1 RESECT DNA DOUBLE-STRAND BREAK ENDS (2008) | 1648 | 1904 |
| CHANG H.H.Y. PANNUNZIO N.R. ADACHI N. LIEBER M.R. NON-HOMOLOGOUS DNA END JOINING AND ALTERNATIVE PATHWAYS TO DOUBLE-STRAND BREAK REPAIR (2017) | 1483 | 1747 |
| JENSEN R.B. CARREIRA A. KOWALCZYKOWSKI S.C. PURIFIED HUMAN BRCA2 STIMULATES RAD51-MEDIATED RECOMBINATION (2010) | 1355 | 2054 |
| Knowledge Base 4: KB 4: Glioblastoma subtyping (n = 1692, density =3.15) | ||
| VERHAAK R.G. HOADLEY K.A. PURDOM E. WANG V. QI Y. WILKERSON M.D. INTEGRATED GENOMIC ANALYSIS IDENTIFIES CLINICALLY RELEVANT SUBTYPES OF GLIOBLASTOM… | 2082 | 2174 |
| COMPREHENSIVE GENOMIC CHARACTERIZATION DEFINES HUMAN GLIOBLASTOMA GENES AND CORE PATHWAYS (2008) | 1731 | 3063 |
| LOUIS D.N. PERRY A. REIFENBERGER G. VON DEIMLING A. FIGARELLA-BRANGER D. CAVENEE W.K. THE 2016 WORLD HEALTH ORGANIZATION CLASSIFICATION OF TUMORS O… | 1693 | 1790 |
| PATEL A.P. TIROSH I. TROMBETTA J.J. SHALEK A.K. GILLESPIE S.M. WAKIMOTO H. CAHILL D.P. MARTUZA R.L. SINGLE-CELL RNA-SEQ HIGHLIGHTS INTRATUMORAL HET… | 1669 | 1822 |
| STUPP R. MASON W.P. VAN DEN BENT M.J. WELLER M. FISHER B. TAPHOORN M.J. RADIOTHERAPY PLUS CONCOMITANT AND ADJUVANT TEMOZOLOMIDE FOR GLIOBLASTOMA (2… | 1660 | 1742 |
| LOUIS D.N. PERRY A. REIFENBERGER G. VON DEIMLING A. FIGARELLA-BRANGER D. CAVENEE W.K. OHGAKI H. ELLISON D.W. THE 2016 WORLD HEALTH ORGANIZATION CLA… | 1627 | 1798 |
| BRENNAN C.W. VERHAAK R.G. MCKENNA A. CAMPOS B. NOUSHMEHR H. SALAMA S.R. THE SOMATIC GENOMIC LANDSCAPE OF GLIOBLASTOMA (2013) | 1599 | 1659 |
| VERHAAK R.G. HOADLEY K.A. PURDOM E. WANG V. QI Y. WILKERSON M.D. MILLER C.R. MESIROV J.P. INTEGRATED GENOMIC ANALYSIS IDENTIFIES CLINICALLY RELEVAN… | 1425 | 1495 |
| PATEL A.P. TIROSH I. TROMBETTA J.J. SHALEK A.K. GILLESPIE S.M. WAKIMOTO H. SINGLE-CELL RNA-SEQ HIGHLIGHTS INTRATUMORAL HETEROGENEITY IN PRIMARY GLI… | 1363 | 1433 |
| CECCARELLI M. BARTHEL F.P. MALTA T.M. SABEDOT T.S. SALAMA S.R. MURRAY B.A. MOLECULAR PROFILING REVEALS BIOLOGICALLY DISCRETE SUBSETS AND PATHWAYS O… | 1295 | 1367 |
| Knowledge Base 5: KB 5: DNA damage and repair mechanisms in cancer 2 (n = 1555, density =4.48) | ||
| ZEMAN M.K. CIMPRICH K.A. CAUSES AND CONSEQUENCES OF REPLICATION STRESS (2014) | 3759 | 5050 |
| ZOU L. ELLEDGE S.J. SENSING DNA DAMAGE THROUGH ATRIP RECOGNITION OF RPA-SSDNA COMPLEXES (2003) | 2551 | 4033 |
| BHOWMICK R. MINOCHERHOMJI S. HICKSON I.D. RAD52 FACILITATES MITOTIC DNA SYNTHESIS FOLLOWING REPLICATION STRESS (2016) | 2442 | 3424 |
| PETERMANN E. ORTA M.L. ISSAEVA N. SCHULTZ N. HELLEDAY T. HYDROXYUREA-STALLED REPLICATION FORKS BECOME PROGRESSIVELY INACTIVATED AND REQUIRE TWO DIF… | 2218 | 2730 |
| SCHLACHER K. CHRIST N. SIAUD N. EGASHIRA A. WU H. JASIN M. DOUBLE-STRAND BREAK REPAIR-INDEPENDENT ROLE FOR BRCA2 IN BLOCKING STALLED REPLICATION FO… | 2109 | 3056 |
| SCHLACHER K. WU H. JASIN M. A DISTINCT REPLICATION FORK PROTECTION PATHWAY CONNECTS FANCONI ANEMIA TUMOR SUPPRESSORS TO RAD51-BRCA1/2 (2012) | 1971 | 2719 |
| NEELSEN K.J. LOPES M. REPLICATION FORK REVERSAL IN EUKARYOTES: FROM DEAD END TO DYNAMIC RESPONSE (2015) | 1761 | 2043 |
| CIMPRICH K.A. CORTEZ D. ATR: AN ESSENTIAL REGULATOR OF GENOME INTEGRITY (2008) | 1713 | 2293 |
| ZELLWEGER R. DALCHER D. MUTREJA K. BERTI M. SCHMID J.A. HERRADOR R. VINDIGNI A. LOPES M. RAD51-MEDIATED REPLICATION FORK REVERSAL IS A GLOBAL RESPO… | 1511 | 1883 |
| HASHIMOTO Y. RAY CHAUDHURI A. LOPES M. COSTANZO V. RAD51 PROTECTS NASCENT DNA FROM MRE11-DEPENDENT DEGRADATION AND PROMOTES CONTINUOUS DNA SYNTHESI… | 1137 | 1334 |
| Knowledge Base 6: KB 6: Autophagy in cancer (n = 1337, density =5.71) | ||
| MIZUSHIMA N. KOMATSU M. AUTOPHAGY: RENOVATION OF CELLS AND TISSUES (2011) | 2064 | 2080 |
| WHITE E. THE ROLE FOR AUTOPHAGY IN CANCER (2015) | 1629 | 1738 |
| STROHECKER A.M. GUO J.Y. KARSLI-UZUNBAS G. PRICE S.M. CHEN G.J. MATHEW R. MCMAHON M. WHITE E. AUTOPHAGY SUSTAINS MITOCHONDRIAL GLUTAMINE METABOLISM… | 1516 | 1580 |
| YUE Z. JIN S. YANG C. LEVINE A.J. HEINTZ N. BECLIN 1 AN AUTOPHAGY GENE ESSENTIAL FOR EARLY EMBRYONIC DEVELOPMENT IS A HAPLOINSUFFICIENT TUMOR SUPPR… | 1470 | 1490 |
| LEVY J.M.M. TOWERS C.G. THORBURN A. TARGETING AUTOPHAGY IN CANCER (2017) | 1464 | 1486 |
| WEI H. WEI S. GAN B. PENG X. ZOU W. GUAN J.L. SUPPRESSION OF AUTOPHAGY BY FIP200 DELETION INHIBITS MAMMARY TUMORIGENESIS (2011) | 1263 | 1296 |
| WHITE E. DECONVOLUTING THE CONTEXT-DEPENDENT ROLE FOR AUTOPHAGY IN CANCER (2012) | 1159 | 1229 |
| YANG A. RAJESHKUMAR N.V. WANG X. YABUUCHI S. ALEXANDER B.M. CHU G.C. VON HOFF D.D. KIMMELMAN A.C. AUTOPHAGY IS CRITICAL FOR PANCREATIC TUMOR GROWTH… | 1140 | 1217 |
| AMARAVADI R. KIMMELMAN A.C. WHITE E. RECENT INSIGHTS INTO THE FUNCTION OF AUTOPHAGY IN CANCER (2016) | 1130 | 1158 |
| LOCK R. KENIFIC C.M. LEIDAL A.M. SALAS E. DEBNATH J. AUTOPHAGY-DEPENDENT PRODUCTION OF SECRETED FACTORS FACILITATES ONCOGENIC RAS-DRIVEN INVASION (… | 1118 | 1130 |
| Knowledge Base 7: KB 7: Glioblastoma genomics 1 (n = 708, density =6.27) | ||
| BRENNAN C.W. THE SOMATIC GENOMIC LANDSCAPE OF GLIOBLASTOMA (2013) | 1413 | 1530 |
| PATEL A.P. SINGLE-CELL RNA-SEQ HIGHLIGHTS INTRATUMORAL HETEROGENEITY IN PRIMARY GLIOBLASTOMA (2014) | 1140 | 1223 |
| VERHAAK R.G. INTEGRATED GENOMIC ANALYSIS IDENTIFIES CLINICALLY RELEVANT SUBTYPES OF GLIOBLASTOMA CHARACTERIZED BY ABNORMALITIES IN PDGFRA IDH1 EGFR… | 795 | 871 |
| STUPP R. RADIOTHERAPY PLUS CONCOMITANT AND ADJUVANT TEMOZOLOMIDE FOR GLIOBLASTOMA (2005) | 677 | 737 |
| CECCARELLI M. MOLECULAR PROFILING REVEALS BIOLOGICALLY DISCRETE SUBSETS AND PATHWAYS OF PROGRESSION IN DIFFUSE GLIOMA (2016) | 675 | 708 |
| LOVE M.I. HUBER W. ANDERS S. MODERATED ESTIMATION OF FOLD CHANGE AND DISPERSION FOR RNA-SEQ DATA WITH DESEQ2 (2014) | 561 | 877 |
| BUTLER A. HOFFMAN P. SMIBERT P. PAPALEXI E. SATIJA R. INTEGRATING SINGLE-CELL TRANSCRIPTOMIC DATA ACROSS DIFFERENT CONDITIONS TECHNOLOGIES AND SPEC… | 558 | 659 |
| WANG Q. TUMOR EVOLUTION OF GLIOMA-INTRINSIC GENE EXPRESSION SUBTYPES ASSOCIATES WITH IMMUNOLOGICAL CHANGES IN THE MICROENVIRONMENT (2017) | 537 | 580 |
| LOUIS D.N. THE 2016 WORLD HEALTH ORGANIZATION CLASSIFICATION OF TUMORS OF THE CENTRAL NERVOUS SYSTEM: A SUMMARY (2016) | 508 | 531 |
| DOBIN A. STAR: ULTRAFAST UNIVERSAL RNA-SEQ ALIGNER (2013) | 508 | 539 |
| Knowledge Base 8: KB 8: Glioblastoma genomics 2 (n = 653, density =9.97) | ||
| STUPP R. MASON W.P. VAN DEN BENT M.J. RADIOTHERAPY PLUS CONCOMITANT AND ADJUVANT TEMOZOLOMIDE FOR GLIOBLASTOMA (2005) | 2127 | 2286 |
| LOUIS D.N. PERRY A. REIFENBERGER G. THE 2016 WORLD HEALTH ORGANIZATION CLASSIFICATION OF TUMORS OF THE CENTRAL NERVOUS SYSTEM: A SUMMARY (2016) | 2075 | 2191 |
| HEGI M.E. DISERENS A.C. GORLIA T. MGMT GENE SILENCING AND BENEFIT FROM TEMOZOLOMIDE IN GLIOBLASTOMA (2005) | 1487 | 1537 |
| YAN H. PARSONS D.W. JIN G. IDH1 AND IDH2 MUTATIONS IN GLIOMAS (2009) | 1464 | 1557 |
| BRENNAN C.W. VERHAAK R.G. MCKENNA A. THE SOMATIC GENOMIC LANDSCAPE OF GLIOBLASTOMA (2013) | 1163 | 1239 |
| PARSONS D.W. JONES S. ZHANG X. AN INTEGRATED GENOMIC ANALYSIS OF HUMAN GLIOBLASTOMA MULTIFORME (2008) | 1070 | 1121 |
| PATEL A.P. TIROSH I. TROMBETTA J.J. SINGLE-CELL RNA-SEQ HIGHLIGHTS INTRATUMORAL HETEROGENEITY IN PRIMARY GLIOBLASTOMA (2014) | 1045 | 1096 |
| VERHAAK R.G. HOADLEY K.A. PURDOM E. INTEGRATED GENOMIC ANALYSIS IDENTIFIES CLINICALLY RELEVANT SUBTYPES OF GLIOBLASTOMA CHARACTERIZED BY ABNORMALIT… | 926 | 997 |
| CECCARELLI M. BARTHEL F.P. MALTA T.M. MOLECULAR PROFILING REVEALS BIOLOGICALLY DISCRETE SUBSETS AND PATHWAYS OF PROGRESSION IN DIFFUSE GLIOMA (2016) | 822 | 864 |
| STUPP R. HEGI M.E. MASON W.P. EFFECTS OF RADIOTHERAPY WITH CONCOMITANT AND ADJUVANT TEMOZOLOMIDE VERSUS RADIOTHERAPY ALONE ON SURVIVAL IN GLIOBLAST… | 775 | 818 |
Note: This analysis refers the bibliographic
coupling analysis, where original publications are the unit of analysis.
Identified research areas can be interpreted as the field’s current
research frontier. See Technical descriptionfor additional
explanations.
| AU | PY | TI | dgr_int | TC | TC_year |
|---|---|---|---|---|---|
| Research Area 1: RA 1: Cancer immunotherapy (n = 993, density =0.28) | |||||
| CHEN DS;MELLMAN I | 2017 | ELEMENTS OF CANCER IMMUNITY AND THE CANCER-IMMUNE SET POINT | 6.94 | 2201 | 440.20 |
| ANTONIA SJ;VILLEGAS A;… | 2017 | DURVALUMAB AFTER CHEMORADIOTHERAPY IN STAGE III NON–SMALL-CELL LUNG CANCER | 5.03 | 2218 | 443.60 |
| AYERS M;LUNCEFORD J;NE… | 2017 | IFN-Γ-RELATED MRNA PROFILE PREDICTS CLINICAL RESPONSE TO PD-1 BLOCKADE | 6.42 | 1478 | 295.60 |
| ALSAAB HO;SAU S;ALZHRA… | 2017 | PD-1 AND PD-L1 CHECKPOINT SIGNALING INHIBITION FOR CANCER IMMUNOTHERAPY: MECHANISM, COMBINATIONS, AND CLINICAL OUTCOME | 10.65 | 834 | 166.80 |
| RIBAS A;DUMMER R;PUZAN… | 2017 | ONCOLYTIC VIROTHERAPY PROMOTES INTRATUMORAL T CELL INFILTRATION AND IMPROVES ANTI-PD-1 IMMUNOTHERAPY | 10.03 | 779 | 155.80 |
| MARIATHASAN S;TURLEY S… | 2018 | TGFΒ ATTENUATES TUMOUR RESPONSE TO PD-L1 BLOCKADE BY CONTRIBUTING TO EXCLUSION OF T CELLS | 3.07 | 1761 | 440.25 |
| SKOULIDIS F;GOLDBERG M… | 2018 | STK11/LKB1 MUTATIONS AND PD-1 INHIBITOR RESISTANCE IN KRAS-MUTANT LUNG ADENOCARCINOMA | 5.90 | 663 | 165.75 |
| RIAZ N;HAVEL JJ;MAKARO… | 2017 | TUMOR AND MICROENVIRONMENT EVOLUTION DURING IMMUNOTHERAPY WITH NIVOLUMAB | 4.11 | 825 | 165.00 |
| DONG Z-Y;ZHONG W-Z;ZHA… | 2017 | POTENTIAL PREDICTIVE VALUE OF TP53 AND KRAS MUTATION STATUS FOR RESPONSE TO PD-1 BLOCKADE IMMUNOTHERAPY IN LUNG ADENOCARCI… | 7.16 | 465 | 93.00 |
| HUANG AC;POSTOW MA;ORL… | 2017 | T-CELL INVIGORATION TO TUMOUR BURDEN RATIO ASSOCIATED WITH ANTI-PD-1 RESPONSE | 3.56 | 863 | 172.60 |
| Research Area 2: RA 2: Replication stress in cancer (n = 932, density =0.3) | |||||
| BLACKFORD AN;JACKSON SP | 2017 | ATM, ATR, AND DNA-PK: THE TRINITY AT THE HEART OF THE DNA DAMAGE RESPONSE | 5.25 | 792 | 158.40 |
| SCULLY R;PANDAY A;ELAN… | 2019 | DNA DOUBLE-STRAND BREAK REPAIR-PATHWAY CHOICE IN SOMATIC MAMMALIAN CELLS | 9.35 | 397 | 132.33 |
| SALDIVAR JC;CORTEZ D;C… | 2017 | THE ESSENTIAL KINASE ATR: ENSURING FAITHFUL DUPLICATION OF A CHALLENGING GENOME | 5.88 | 342 | 68.40 |
| CECCALDI R;RONDINELLI … | 2016 | REPAIR PATHWAY CHOICES AND CONSEQUENCES AT THE DOUBLE-STRAND BREAK | 2.46 | 768 | 128.00 |
| BHOWMICK R;MINOCHERHOM… | 2016 | RAD52 FACILITATES MITOTIC DNA SYNTHESIS FOLLOWING REPLICATION STRESS | 6.71 | 198 | 33.00 |
| SOTIRIOU SK;KAMILERI I… | 2016 | MAMMALIAN RAD52 FUNCTIONS IN BREAK-INDUCED REPLICATION REPAIR OF COLLAPSED DNA REPLICATION FORKS | 7.31 | 166 | 27.67 |
| RANJHA L;HOWARD SM;CEJ… | 2018 | MAIN STEPS IN DNA DOUBLE-STRAND BREAK REPAIR: AN INTRODUCTION TO HOMOLOGOUS RECOMBINATION AND RELATED PROCESSES | 7.67 | 148 | 37.00 |
| LEMAÇON D;JACKSON J;QU… | 2017 | MRE11 AND EXO1 NUCLEASES DEGRADE REVERSED FORKS AND ELICIT MUS81-DEPENDENT FORK RESCUE IN BRCA2-DEFICIENT CELLS | 6.28 | 180 | 36.00 |
| ANAND R;RANJHA L;CANNA… | 2016 | PHOSPHORYLATED CTIP FUNCTIONS AS A CO-FACTOR OF THE MRE11-RAD50-NBS1 ENDONUCLEASE IN DNA END RESECTION | 6.81 | 164 | 27.33 |
| BERTI M;VINDIGNI A | 2016 | REPLICATION STRESS: GETTING BACK ON TRACK | 7.07 | 151 | 25.17 |
| Research Area 3: RA 3: Cancer metabolism (n = 819, density =0.3) | |||||
| PAVLOVA NN;THOMPSON CB | 2016 | THE EMERGING HALLMARKS OF CANCER METABOLISM | 5.17 | 2546 | 424.33 |
| DE BERARDINIS RJ;CHAND… | 2016 | FUNDAMENTALS OF CANCER METABOLISM | 6.70 | 1281 | 213.50 |
| VANDER HEIDEN MG;DEBER… | 2017 | UNDERSTANDING THE INTERSECTIONS BETWEEN METABOLISM AND CANCER BIOLOGY | 7.27 | 981 | 196.20 |
| DUCKER GS;RABINOWITZ JD | 2017 | ONE-CARBON METABOLISM IN HEALTH AND DISEASE | 6.81 | 738 | 147.60 |
| VYAS S;ZAGANJOR E;HAIG… | 2016 | MITOCHONDRIA AND CANCER | 5.74 | 813 | 135.50 |
| ZONG W-X;RABINOWITZ JD… | 2016 | MITOCHONDRIA AND CANCER | 6.44 | 518 | 86.33 |
| ALTMAN BJ;STINE ZE;DAN… | 2016 | FROM KREBS TO CLINIC: GLUTAMINE METABOLISM TO CANCER THERAPY | 2.96 | 917 | 152.83 |
| LUENGO A;GUI DY;VANDER… | 2017 | TARGETING METABOLISM FOR CANCER THERAPY | 6.59 | 403 | 80.60 |
| YANG M;VOUSDEN KH | 2016 | SERINE AND ONE-CARBON METABOLISM IN CANCER | 5.84 | 433 | 72.17 |
| PANIERI E;SANTORO MM | 2016 | ROS HOMEOSTASIS AND METABOLISM: A DANGEROUS LIASON IN CANCER CELLS | 3.69 | 629 | 104.83 |
| Research Area 4: RA 4: glioblastoma subtyping (n = 559, density =0.26) | |||||
| CECCARELLI M;BARTHEL F… | 2016 | MOLECULAR PROFILING REVEALS BIOLOGICALLY DISCRETE SUBSETS AND PATHWAYS OF PROGRESSION IN DIFFUSE GLIOMA | 3.82 | 1127 | 187.83 |
| WANG Q;HU B;HU X;KIM H… | 2017 | TUMOR EVOLUTION OF GLIOMA-INTRINSIC GENE EXPRESSION SUBTYPES ASSOCIATES WITH IMMUNOLOGICAL CHANGES IN THE MICROENVIRONMENT | 5.07 | 671 | 134.20 |
| NEFTEL C;LAFFY J;FILBI… | 2019 | AN INTEGRATIVE MODEL OF CELLULAR STATES, PLASTICITY, AND GENETICS FOR GLIOBLASTOMA | 5.05 | 562 | 187.33 |
| COLAPRICO A;SILVA TC;O… | 2016 | TCGABIOLINKS: AN R/BIOCONDUCTOR PACKAGE FOR INTEGRATIVE ANALYSIS OF TCGA DATA | 1.69 | 1182 | 197.00 |
| JACOB F;SALINAS RD;ZHA… | 2020 | A PATIENT-DERIVED GLIOBLASTOMA ORGANOID MODEL AND BIOBANK RECAPITULATES INTER- AND INTRA-TUMORAL HETEROGENEITY | 4.15 | 246 | 123.00 |
| SEGERMAN A;NIKLASSON M… | 2016 | CLONAL VARIATION IN DRUG AND RADIATION RESPONSE AMONG GLIOMA-INITIATING CELLS IS LINKED TO PRONEURAL-MESENCHYMAL TRANSITION | 5.99 | 108 | 18.00 |
| MALTA TM;SOKOLOV A;GEN… | 2018 | MACHINE LEARNING IDENTIFIES STEMNESS FEATURES ASSOCIATED WITH ONCOGENIC DEDIFFERENTIATION | 1.12 | 558 | 139.50 |
| HU B;WANG Q;WANG YA;HU… | 2016 | EPIGENETIC ACTIVATION OF WNT5A DRIVES GLIOBLASTOMA STEM CELL DIFFERENTIATION AND INVASIVE GROWTH | 3.55 | 151 | 25.17 |
| LENTING K;VERHAAK R;TE… | 2017 | GLIOMA: EXPERIMENTAL MODELS AND REALITY | 3.26 | 163 | 32.60 |
| LIAU BB;SIEVERS C;DONO… | 2017 | ADAPTIVE CHROMATIN REMODELING DRIVES GLIOBLASTOMA STEM CELL PLASTICITY AND DRUG TOLERANCE | 2.25 | 231 | 46.20 |
| Research Area 5: RA 5: glioma molecular subtypes (n = 446, density =0.56) | |||||
| BEHNAN J;FINOCCHIARO G… | 2019 | THE LANDSCAPE OF THE MESENCHYMAL SIGNATURE IN BRAIN TUMOURS | 9.09 | 123 | 41.00 |
| CHEN Z;HAMBARDZUMYAN D | 2018 | IMMUNE MICROENVIRONMENT IN GLIOBLASTOMA SUBTYPES | 4.98 | 167 | 41.75 |
| PATEL SH;POISSON LM;BR… | 2017 | T2–FLAIR MISMATCH, AN IMAGING BIOMARKER FOR IDH AND 1P/19Q STATUS IN LOWER-GRADE GLIOMAS: A TCGA/TCIA PROJECT | 5.05 | 153 | 30.60 |
| JOHANNS TM;MILLER CA;D… | 2016 | IMMUNOGENOMICS OF HYPERMUTATED GLIOBLASTOMA: A PATIENT WITH GERMLINE POLE DEFICIENCY TREATED WITH CHECKPOINT BLOCKADE IMMU… | 3.35 | 202 | 33.67 |
| DANIEL P;SABRI S;CHADD… | 2019 | TEMOZOLOMIDE INDUCED HYPERMUTATION IN GLIOMA: EVOLUTIONARY MECHANISMS AND THERAPEUTIC OPPORTUNITIES | 7.59 | 86 | 28.67 |
| AN Z;AKSOY O;ZHENG T;F… | 2018 | EPIDERMAL GROWTH FACTOR RECEPTOR AND EGFRVIII IN GLIOBLASTOMA: SIGNALING PATHWAYS AND TARGETED THERAPIES | 3.21 | 200 | 50.00 |
| ZHANG C;CHENG W;REN X;… | 2017 | TUMOR PURITY AS AN UNDERLYING KEY FACTOR IN GLIOMA | 3.24 | 177 | 35.40 |
| ZHAO Z;ZHANG K-N;WANG … | 2021 | CHINESE GLIOMA GENOME ATLAS (CGGA): A COMPREHENSIVE RESOURCE WITH FUNCTIONAL GENOMIC DATA FROM CHINESE GLIOMA PATIENTS | 3.91 | 107 | 107.00 |
| JONSSON P;LIN AL;YOUNG… | 2019 | GENOMIC CORRELATES OF DISEASE PROGRESSION AND TREATMENT RESPONSE IN PROSPECTIVELY CHARACTERIZED GLIOMAS | 6.93 | 54 | 18.00 |
| KARSY M;GUAN J;COHEN A… | 2017 | NEW MOLECULAR CONSIDERATIONS FOR GLIOMA: IDH, ATRX, BRAF, TERT, H3 K27M | 4.99 | 69 | 13.80 |
| Research Area 6: RA 6: Immune checkpoint therapy in cancer (n = 445, density =0.9) | |||||
| BUCHBINDER EI;DESAI A | 2016 | CTLA-4 AND PD-1 PATHWAYS SIMILARITIES, DIFFERENCES, AND IMPLICATIONS OF THEIR INHIBITION | 10.43 | 1093 | 182.17 |
| HORN L;SPIGEL DR;VOKES… | 2017 | NIVOLUMAB VERSUS DOCETAXEL IN PREVIOUSLY TREATED PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER: TWO-YEAR OUTCOMES FROM… | 8.81 | 512 | 102.40 |
| LESOKHIN AM;ANSELL SM;… | 2016 | NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCY: PRELIMINARY RESULTS OF A PHASE IB STUDY | 5.93 | 674 | 112.33 |
| RIBAS A;HAMID O;DAUD A… | 2016 | ASSOCIATION OF PEMBROLIZUMAB WITH TUMOR RESPONSE AND SURVIVAL AMONG PATIENTS WITH ADVANCED MELANOMA | 5.37 | 696 | 116.00 |
| MASSARD C;GORDON MS;SH… | 2016 | SAFETY AND EFFICACY OF DURVALUMAB (MEDI4736), AN ANTI-PROGRAMMED CELL DEATH LIGAND-1 IMMUNE CHECKPOINT INHIBITOR, IN PATIE… | 5.98 | 622 | 103.67 |
| ARMAND P;SHIPP MA;RIBR… | 2016 | PROGRAMMED DEATH-1 BLOCKADE WITH PEMBROLIZUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE | 6.43 | 481 | 80.17 |
| GARASSINO MC;CHO B-C;K… | 2018 | DURVALUMAB AS THIRD-LINE OR LATER TREATMENT FOR ADVANCED NON-SMALL-CELL LUNG CANCER (ATLANTIC): AN OPEN-LABEL, SINGLE-ARM,… | 8.67 | 336 | 84.00 |
| D’ANGELO SP;MAHONEY MR… | 2018 | NIVOLUMAB WITH OR WITHOUT IPILIMUMAB TREATMENT FOR METASTATIC SARCOMA (ALLIANCE A091401): TWO OPEN-LABEL, NON-COMPARATIVE,… | 7.57 | 301 | 75.25 |
| ETTINGER DS;WOOD DE;AK… | 2016 | NCCN GUIDELINES® INSIGHTS: NON-SMALL CELL LUNG CANCER, VERSION 4.2016 FEATURED UPDATES TO THE NCCN GUIDELINES | 7.43 | 302 | 50.33 |
| BALAR AV;CASTELLANO D;… | 2017 | FIRST-LINE PEMBROLIZUMAB IN CISPLATIN-INELIGIBLE PATIENTS WITH LOCALLY ADVANCED AND UNRESECTABLE OR METASTATIC UROTHELIAL … | 2.80 | 704 | 140.80 |
| Research Area 7: RA 7: Autophagy in cancer (n = 396, density =0.35) | |||||
| LEVY JMM;TOWERS CG;THO… | 2017 | TARGETING AUTOPHAGY IN CANCER | 2.74 | 1218 | 243.60 |
| KIMMELMAN AC;WHITE E | 2017 | AUTOPHAGY AND TUMOR METABOLISM | 5.81 | 454 | 90.80 |
| AMARAVADI R;KIMMELMAN … | 2016 | RECENT INSIGHTS INTO THE FUNCTION OF AUTOPHAGY IN CANCER | 5.50 | 462 | 77.00 |
| DIKIC I;ELAZAR Z | 2018 | MECHANISM AND MEDICAL IMPLICATIONS OF MAMMALIAN AUTOPHAGY | 1.90 | 1130 | 282.50 |
| AMARAVADI RK;KIMMELMAN… | 2019 | TARGETING AUTOPHAGY IN CANCER: RECENT ADVANCES AND FUTURE DIRECTIONS | 3.09 | 310 | 103.33 |
| GUO JY;TENG X;LADDHA S… | 2016 | AUTOPHAGY PROVIDES METABOLIC SUBSTRATES TO MAINTAIN ENERGY CHARGE AND NUCLEOTIDE POOLS IN RAS-DRIVEN LUNG CANCER CELLS | 3.37 | 217 | 36.17 |
| WHITE E | 2016 | AUTOPHAGY AND P53 | 4.14 | 171 | 28.50 |
| MOWERS EE;SHARIFI MN;M… | 2017 | AUTOPHAGY IN CANCER METASTASIS | 2.45 | 286 | 57.20 |
| ONORATI AV;DYCZYNSKI M… | 2018 | TARGETING AUTOPHAGY IN CANCER | 2.31 | 277 | 69.25 |
| SHARIFI MN;MOWERS EE;D… | 2016 | AUTOPHAGY PROMOTES FOCAL ADHESION DISASSEMBLY AND CELL MOTILITY OF METASTATIC TUMOR CELLS THROUGH THE DIRECT INTERACTION O… | 3.37 | 183 | 30.50 |
| Research Area 8: RA 8: Glioblastoma subtypes and treatment (n = 395, density =0.95) | |||||
| STUPP R;TAILLIBERT S;K… | 2017 | EFFECT OF TUMOR-TREATING FIELDS PLUS MAINTENANCE TEMOZOLOMIDE VS MAINTENANCE TEMOZOLOMIDE ALONE ON SURVIVAL IN PATIENTS WI… | 8.59 | 855 | 171.00 |
| WELLER M;BUTOWSKI N;TR… | 2017 | RINDOPEPIMUT WITH TEMOZOLOMIDE FOR PATIENTS WITH NEWLY DIAGNOSED, EGFRVIII-EXPRESSING GLIOBLASTOMA (ACT IV): A RANDOMISED,… | 7.13 | 495 | 99.00 |
| HERRLINGER U;TZARIDIS … | 2019 | LOMUSTINE-TEMOZOLOMIDE COMBINATION THERAPY VERSUS STANDARD TEMOZOLOMIDE THERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLAST… | 9.07 | 213 | 71.00 |
| CHEN R;SMITH-COHN M;CO… | 2017 | GLIOMA SUBCLASSIFICATIONS AND THEIR CLINICAL SIGNIFICANCE | 5.25 | 280 | 56.00 |
| TOUAT M;IDBAIH A;SANSO… | 2017 | GLIOBLASTOMA TARGETED THERAPY: UPDATED APPROACHES FROM RECENT BIOLOGICAL INSIGHTS | 5.97 | 226 | 45.20 |
| VAN DEN BENT MJ;BAUMER… | 2017 | INTERIM RESULTS FROM THE CATNON TRIAL (EORTC STUDY 26053-22054) OF TREATMENT WITH CONCURRENT AND ADJUVANT TEMOZOLOMIDE FOR… | 5.18 | 204 | 40.80 |
| DANG L;YEN K;ATTAR EC | 2016 | IDH MUTATIONS IN CANCER AND PROGRESS TOWARD DEVELOPMENT OF TARGETED THERAPEUTICS | 3.41 | 270 | 45.00 |
| QAZI MA;VORA P;VENUGOP… | 2017 | INTRATUMORAL HETEROGENEITY: PATHWAYS TO TREATMENT RESISTANCE AND RELAPSE IN HUMAN GLIOBLASTOMA | 5.27 | 163 | 32.60 |
| KICKINGEREDER P;NEUBER… | 2018 | RADIOMIC SUBTYPING IMPROVES DISEASE STRATIFICATION BEYOND KEY MOLECULAR, CLINICAL, AND STANDARD IMAGING CHARACTERISTICS IN… | 7.02 | 111 | 27.75 |
| AOKI K;NAKAMURA H;SUZU… | 2018 | PROGNOSTIC RELEVANCE OF GENETIC ALTERATIONS IN DIFFUSE LOWER-GRADE GLIOMAS | 5.58 | 130 | 32.50 |
| Research Area 9: RA 9: Disease progression in glioblastoma (n = 301, density =0.64) | |||||
| WANG J;CAZZATO E;LADEW… | 2016 | CLONAL EVOLUTION OF GLIOBLASTOMA UNDER THERAPY | 5.68 | 380 | 63.33 |
| FLAVAHAN WA;DRIER Y;LI… | 2016 | INSULATOR DYSFUNCTION AND ONCOGENE ACTIVATION IN IDH MUTANT GLIOMAS | 2.79 | 700 | 116.67 |
| LAN X;JÖRG DJ;CAVALLI … | 2017 | FATE MAPPING OF HUMAN GLIOBLASTOMA REVEALS AN INVARIANT STEM CELL HIERARCHY | 5.52 | 191 | 38.20 |
| CAPPER D;JONES DTW;SIL… | 2018 | DNA METHYLATION-BASED CLASSIFICATION OF CENTRAL NERVOUS SYSTEM TUMOURS | 1.06 | 976 | 244.00 |
| ZHAO J;CHEN AX;GARTREL… | 2019 | IMMUNE AND GENOMIC CORRELATES OF RESPONSE TO ANTI-PD-1 IMMUNOTHERAPY IN GLIOBLASTOMA | 2.98 | 323 | 107.67 |
| BARTHEL FP;JOHNSON KC;… | 2019 | LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS | 6.60 | 136 | 45.33 |
| REIFENBERGER G;WIRSCHI… | 2017 | ADVANCES IN THE MOLECULAR GENETICS OF GLIOMAS-IMPLICATIONS FOR CLASSIFICATION AND THERAPY | 2.69 | 323 | 64.60 |
| BEN-DAVID U;SIRANOSIAN… | 2018 | GENETIC AND TRANSCRIPTIONAL EVOLUTION ALTERS CANCER CELL LINE DRUG RESPONSE | 2.12 | 366 | 91.50 |
| MILLER AM;SHAH RH;PENT… | 2019 | TRACKING TUMOUR EVOLUTION IN GLIOMA THROUGH LIQUID BIOPSIES OF CEREBROSPINAL FLUID | 3.69 | 205 | 68.33 |
| OSUKA S;VAN MEIR EG | 2017 | OVERCOMING THERAPEUTIC RESISTANCE IN GLIOBLASTOMA: THE WAY FORWARD | 3.14 | 229 | 45.80 |
All results are preliminary so far…